Abstract 118P
Background
The MET14 skipping mutation, prevalent in various tumors, notably in non-small cell lung cancer (NSCLC), is strongly associated with specific therapeutic targets. Our study aimed to detect MET14 skipping in pan-solid tumor samples using DNA and RNA next-generation sequencing NGS, evaluating assay sensitivity and specificity and mutation distribution across tumor types and populations.
Methods
8,049 samples were tested for MET14 skipping by DNA and RNA-based NGS in amplicon library constructs (ALC), while 7,676 samples were tested by DNA-based NGS in capture library constructs (CLC), with the analysis focusing on clinically significant mutations.
Results
In patients undergoing concurrent DNA/RNA-based NGS (ALC), 1.64% (132/8049) were positive, with lung cancer (LC) showing the highest rate at 2.12% (119/5618), followed by gastrointestinal tumors at 0.11% (3/2681). Lung sarcomatoid carcinoma had the highest MET14 skipping rate (13.6%; 3/22) among LC subtypes. The detection rates of patients with synchronized testing who tested positive by RNA or DNA-based NGS were 1.46% (123/8409) and 0.43% (36/8409), respectively. The detection rate of DNA-based NGS(CLC) was 0.55% (42/7676). Among simultaneously tested patients, 1.20% (96) of the 8,013 DNA-negative cases showed positive results on RNA testing, possibly due to probe design limitations at the Y1003 locus on the DNA level. Conversely, 9 of 36 DNA-positive cases were RNA-negative, indicating possible false-positive and false-negative problems with DNA detection. DNA NGS-based analysis showed that the splice donor site (SD) had the highest mutation rate at 28.3%. In addition, there was no significant difference in the detection rate of MET14 skipping between different tumor cell contents, sample types (e.g., pleural fluid vs. other tissues), and primary vs. metastatic foci (p>0.05). MET14 skipping was more frequent in patients aged 60 years and older (p<0.05), while there was no significant correlation between gender and detection rate.
Conclusions
RNA-based NGS is more accurate in detecting MET14 skipping mutations, and can directly recognize exons lost after transcription, independent of intronic variants, which effectively improves the accuracy of detection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Development of a cadherin-17 (CDH17) immunohistochemistry assay for use as a companion diagnostic for cabotamig in gastrointestinal cancers
Presenter: Dennis Wong
Session: Poster session 08
184P - From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis
Presenter: Kristian Egebjerg
Session: Poster session 08
185P - Multi-omics profiling and clinical characterization of colon-like cancer of unknown primary (CUP)
Presenter: Maria Pouyiourou
Session: Poster session 08
186P - Differences in antigen and immune marker expression in lymphoepithelioma-like carcinoma (LELC) and nasopharyngeal carcinoma (NPC): A multiplex immunohistochemistry (mIHC), spatial transcriptomic and multiplex immunofluorescence (mIF)-based analysis
Presenter: Daniel Peh
Session: Poster session 08
187P - Organoid growth-based oncological sensitivity test (OncoSensi) for predicting radiation therapy outcomes in pharyngeal and esophageal cancer
Presenter: Dong Woo Lee
Session: Poster session 08
188P - Integration of immunohistochemistry and transcriptomics reveals new insights into the immune landscape of soft-tissue sarcomas
Presenter: Giulia Petroni
Session: Poster session 08
189P - An image-based deep learning prediction model for characterization of the drug tolerant persister cell state
Presenter: Lauren Cech
Session: Poster session 08
190P - A large scale proteogenomics atlas for precision oncology research
Presenter: Timothy Anthony Yap
Session: Poster session 08
191P - Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven tumors
Presenter: Francesco Facchinetti
Session: Poster session 08
192P - Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers
Presenter: Daniel Palmer
Session: Poster session 08